vertex pharmaceuticals news - Search News

Hosted on MSN · 12h

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,

MarketWatch · 4h

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

This was the stock's fourth consecutive day of gains.

Zacks.com on MSN · 2d

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 and touched a low of $401.

MarketWatch · 2d

Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market

This was the stock's third consecutive day of gains.

4don MSN

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

3d

Vertex wins approval for new once-daily CF drug

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

2d

Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

13h

Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

2d

Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...

7d

Vertex's painkiller results match placebo in study, shares tumble

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

1d

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...

Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results